Nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy was granted approval by the European Medicines Agency for first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, esophagogastric junction cancer or esophageal adenocarcinoma whose tumors express PD-L1 with CPS ≥ 5 (https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo). Here, CD274 is linked to esophageal adenocarcinoma.